| 摘要 |
FIELD: medicine. ^ SUBSTANCE: there are described target-specific compounds representing glucagon-like protein-1 (GLP-1R) receptor agonist conjugates with a linker covalently bound with an antigen-binding antibody site. The invention also refers to methods for preventing or treating diabetes or diabetes-associated conditions. ^ EFFECT: compounds maintain insulnotropic activity combined with manifestation of prolonged elimination half-life. ^ 39 cl, 44 dwg, 4 tbl, 29 ex |
